Anthem Biosciences Limited, a leading contract research, development, and manufacturing organization (CRDMO), has reported robust financial results for the first quarter of fiscal year 2026, marking its first earnings report since going public.

Financial Highlights

• Consolidated revenue reached INR 540.00 crores, representing a significant 60% year-on-year growth.
• The Contract Research, Development, and Manufacturing (CRDM) business contributed INR 452.70 crores to the total revenue.
• Specialty ingredients segment generated INR 87.50 crores.
• EBITDA stood at INR 214.30 crores with a margin of 38%.
• Profit After Tax (PAT) was INR 135.80 crores, maintaining a 24% margin.
• The company reported a strong net cash position of INR 784.80 crores as of June 30, 2025.

Operational Highlights

• Two molecules progressed from Phase 3 to commercial stage, expanding the commercial portfolio from 10 to 12 products.
• The company added 54 kiloliters of custom synthesis capacity in unit 2 during the quarter.
• Anthem Biosciences maintains a healthy pipeline with 8 molecules currently in Phase 3 clinical trials.

Business Outlook

Ajay Bhardwaj, Managing Director and CEO of Anthem Biosciences, commented on the results, stating, "We have kicked off FY26 with a strong performance, laying a solid foundation for the year ahead. The growth reflects our CRDM revenue stream that started ramping up in Q2 of FY25."

The management expects to maintain historical growth rates of around 20% annually, although they noted that this quarter was exceptional due to the lumpy nature of their business. The growth was primarily driven by increased demand for commercial products across multiple customers.

Capacity Expansion Plans

Anthem Biosciences is continuing its capacity expansion efforts:

• An additional 76 kiloliters of custom synthesis capacity is expected to be completed in unit 2 by the end of the calendar year.
• 25 kiloliters of capacity, including peptide synthesis, will be added in NeoAnthem by the end of the first half of the fiscal year.
• 40 kiloliters of fermentation capacity will be added in NeoAnthem by the end of the calendar year.
• The company has initiated groundbreaking for its unit 4 expansion.

Market Position and Future Outlook

Anthem Biosciences maintains a strong position in the CRDMO space, with a focus on innovative pharmaceuticals. The company is actively working on new modalities such as Antibody-Drug Conjugates (ADCs) and has full capabilities across multiple projects in this area.

The management remains optimistic about future growth prospects, citing ongoing discussions with customers for potential expansion of wallet share and participation in emerging areas such as GLP-1 agonists.

As Anthem Biosciences continues to invest in new technologies and capacity expansion, it aims to strengthen its position as a key player in the global pharmaceutical outsourcing market.

Anthem Biosciences Limited, a leading Contract Research, Development and Manufacturing Organization (CRDMO), has reported robust financial results for the first quarter, while simultaneously advancing its expansion strategy.

Financial Highlights

For Q1, Anthem Biosciences posted impressive growth:

• Consolidated Revenue from Operations surged to ₹5,402.09 crore, marking a 59.5% increase year-over-year.
• EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) reached ₹2,143.00 crore, with an EBITDA margin of 38%.
• Profit After Tax (PAT) stood at ₹1,358.00 crore, representing a substantial 64.8% growth compared to the same quarter last year.
• The company maintained a strong net cash position of ₹7,848.00 crore.

Business Segment Performance

Anthem's growth was driven by strong performances across its key business segments:

• The CRDMO business delivered revenues of ₹4,527.00 crore, contributing 83.8% to the total revenue.
• The Specialty Ingredients segment generated ₹875.00 crore in revenue, accounting for 16.2% of the total.

Expansion and Strategic Initiatives

Alongside its financial performance, Anthem Biosciences is actively expanding its capabilities:

• The company is enhancing its API, intermediates, and formulation capabilities.
• Efforts are underway to strengthen biologics and specialty chemistry services.
• Anthem is leveraging global partnerships to drive revenue growth and improve profit margins.

Operational Developments

Anthem has made significant progress in its operational expansion:

• At Unit II in Harohalli, the company completed and commenced operations of a 54 kL custom synthesis capacity expansion.
• Unit III (NeoAnthem, Harohalli) saw the completion and phased commencement of operations, including:
  • A custom synthesis block with R&D laboratory, pilot laboratory, and kilo laboratory facilities.
  • A new, state-of-the-art 16 kL dedicated commercial scale peptide manufacturing facility.
  • A 2.5 kL commercial scale high-potency manufacturing facility.
• Construction has begun on a new greenfield facility at the 30-acre Unit IV site in Harohalli, Bangalore.

Management Commentary

Ajay Bhardwaj, Chairman, Managing Director and CEO of Anthem Biosciences, commented on the results: "We have kicked off with a strong performance, laying a solid foundation for the year ahead. Strong YoY growth reflects a CRDMO revenue stream that started ramping up since Q2 of the previous fiscal year. A combination of a dedicated team, strategic focus, operational excellence and long-standing client partnerships has helped us deliver performance across both CRDMO and Specialty Ingredients business."

Looking Ahead

With its robust financial performance, ongoing expansion efforts, and strategic focus on innovation and technology, Anthem Biosciences appears well-positioned for continued growth in the CRDMO and specialty ingredients markets. The company's investments in new facilities and capabilities are expected to further strengthen its market position and drive future growth.

Investors and analysts will have the opportunity to discuss these results and future outlook during an earnings call scheduled for August 14 at 12:00 PM (IST).